Daclizumab
Top View
- Daclizumab (Anti-Tac, Zenapax) in the Treatment of Leukemia/Lymphoma
- Adverse Events/Mode of Action Relationship of Monoclonal Antibodies-Based Therapies: Overview of Marketed Products in the European Union
- Daclizumab (Zinbryta) Reference Number: ERX.SPMN.165 Effective Date: 10/16 Coding Implications Last Review Date: 09/16 Revision Log
- Long Term Follow-Up of Tocilizumab in Refractory and Non-Infectious Uveitic Cystoid Macular Edema
- Tailored Therapy for Severe Asthma Francesco Menzella1*, Mirco Lusuardi2, Carla Galeone1 and Luigi Zucchi1
- INN Working Document 05.179 Update 2011
- Zinbryta, INN-Daclizumab
- Daclizumab (Zinbryta) Reference Number: CP.PHAR.269 Effective Date: 08.01.16 Last Review Date: 05.18 Coding Implications Line of Business: Medicaid Revision Log
- As Treatment for Refractory Acute Graft-Versus-Host Disease
- CDER List of Licensed Biological Products With
- (INN) for Biological and Biotechnological Substances
- Blocking Interleukin-4 Enhances Efficacy of Vaccines for Treatment Of
- WO 2018/067987 Al 12 April 2018 (12.04.2018) W !P O PCT
- Treatment and Unmet Needs in Steroid-Refractory Acute Graft-Versus-Host Disease Florent Malard, Xiao-Jun Huang, Joycelyn Sim
- Antibody Drug Nomenclature: -Umab -Zumab -Ximab
- 4 Chimeric and Humanized Antibodies Have a Longer Circulating Half-Life and Reduced Immunogenicity [Adair, F 2002]. 1.5 Objectiv
- WO 2017/011544 Al 19 January 2017 (19.01.2017) P O PCT
- (12) United States Patent (10) Patent No.: US 9,446,134 B2 Maggio (45) Date of Patent: *Sep